Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3%

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 3,410,000 shares, a drop of 12.3% from the November 15th total of 3,890,000 shares. Based on an average trading volume of 476,600 shares, the short-interest ratio is presently 7.2 days.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $4.90 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics has a one year low of $2.71 and a one year high of $6.55. The business’s 50-day moving average price is $5.15 and its two-hundred day moving average price is $4.73.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). Sell-side analysts anticipate that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently added to or reduced their stakes in ALDX. US Bancorp DE bought a new position in shares of Aldeyra Therapeutics during the 3rd quarter valued at $30,000. SG Americas Securities LLC bought a new position in Aldeyra Therapeutics during the second quarter valued at about $38,000. Diversified Trust Co acquired a new stake in shares of Aldeyra Therapeutics in the second quarter worth about $41,000. Laidlaw Wealth Management LLC boosted its stake in shares of Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 4,150 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new position in shares of Aldeyra Therapeutics during the 3rd quarter valued at about $62,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.